Vaccine selectively targets toxic forms of amylo
Author: Michael
Harness Therapeutics has unveiled its second-gene
Algen Biotechnologies is combining CRISPR and AI
At LIC 2025, investors, scientists and founders
The DripBar, an intravenous vitamin therapy franc
Evelyne Bischof on cognition, biomarkers and the
Cirrus Therapeutics lands seed funding to advanc
Klotho Neurosciences today announced it has signe
LifeVantage Corporation said it has closed its pr
Longevity biotech seeks to broaden its therapeut